Saxena, Aditi R.

A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor

Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry

Diabetes Treatment and ManagementReceptor Mechanisms and Signaling

Cited by 192

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Saxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 156

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial

Saxena, A. R., Frias, J. P., Brown, L. S., Gorman, D. N., Vasas, S., Tsamandouras, N., & Birnbaum, M. J. (2023) · JAMA Network Open

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 149

Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology

Amin, N. B., Saxena, A. R., Somayaji, V., & Dullea, R. (2023) · Clinical Therapeutics

Liver Disease Diagnosis and TreatmentLipid metabolism and biosynthesis

Cited by 48

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

Saxena, A. R., Frias, J. P., Gorman, D. N., Lopez, R. N., Andrawis, N., Tsamandouras, N., & Birnbaum, M. J. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 45